ClinicalTrials.gg
RecruitingNCT06261489Updated Sep 15, 2026

Cannabis (THC vs. CBD) in Multiple Sclerosis

A Phase 2 interventional study of THC and CBD in Multiple Sclerosis, sponsored by University of Calgary. Recruiting at 2 sites in Canada. Open to participants aged 26 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by University of Calgary · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
26 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.

Planned enrollment
177th of 215
30 · median 177
Started
2025
with 10 others
Phase 2
48 of 257
3 open now
Primary completion
2027-09
later than 30 of 42 live
Registered
240th of 257
by date
Lead sponsor
7 of 257
University of Calgary

Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 177th largest by planned enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2025, is one of 48 in phase 2, reaches primary completion later than 30 of the 42 other live ones, and was the 240th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 26 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 257 studies in Multiple Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS).

Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.

Read the detailed description

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system.

Cannabis and cannabis-based medicines (CBM) are often used by persons with MS (PwMS).

Cannabis research to date indicates that its use worsens cognitive function in PwMS. Additionally, cognitive impairment (CI) is already a frequent consequence of MS, with a significant negative impact on quality of life (QOL).

This is pilot randomized, double blinded, double arm clinical trial of Tetrahydrocannabinol (THC) 25 mg or Cannabidiol (CBD) 50 mg orally for 15 weeks in people with MS trial.

The investigators will recruit PwMS with symptoms of neurogenic lower urinary tract dysfunction (NLUTD). These participants can either be on a treatment that has been only partially effective (as per patient report) or has never tried an intervention for their NLUTD symptoms.

The primary aim is to evaluate the differential effect of the tetrahydrocannabinol (THC) and cannabidiol (CBD) on cognitive outcomes in persons with Multiple Sclerosis (PwMS) using cannabis for NLUTD.

The results of our proposed study will better inform both healthcare practitioners and patients with respect to the potential risks of treatment with cannabis-based products and any difference with respect to THC vs. CBD-based products.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Cannabis
  • Cognitive Function
04

Who can participate

Ages eligible
26 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 26 and 59 years inclusive.
  • Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) [12]
  • Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7.
  • If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks.
  • Sexually active men and women of must agree to use adequate .
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Major psychiatric disorder such as schizophrenia or bipolar disorder
  • Major neurological disorder which could affect cognition such as dementia, traumatic brain injury.
  • Seizure disorder
  • Use of antipsychotic medication
  • Use of benzodiazepines other than exclusively at night/bedtime
  • Experienced a MS relapse in the last ninety (90) days.
  • Current use of cannabis or CBM greater than 3x/week.
  • Currently using cannabis/CBM less than 3x/week and being unwilling to abstain for the duration of the study.
  • Visual acuity (binocular) worse than 20/70 (in order to complete the cognitive outcomes)
  • Significant upper extremity disability that would interfere with the cognitive tests battery.
  • Indwelling catheter use/urinary diversion
  • Pregnant or Breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Tetrahydrocannabinol (THC) 25 mg

    THC oil will be administered orally once a day for 15 weeks.

    Drug: THC

  • Experimental
    Cannabidiol (CBD) 50 mg

    CBD oil will be administered orally once a day for 15 weeks.

    Drug: CBD

Interventions

  • DrugTHC

    Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.

    Also known as: Tetrahydrocannabinol

  • DrugCBD

    Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.

    Also known as: Cannabidiol

06

What researchers measure

Primary outcomes

  1. Cognitive outcome: The Differential Effect, if any, of THC and CBD in MS Cognition will be measured by Symbol Digit Modality Test (SDMT).

    Symbol Digit Modality Test (SDMT) is an assessment of the information processing speed. It consists of the presentation of a standard letter sized paper (8.5 × 11 in.) that contains the numbers and symbols to be processed. At the top of the page is a key where nine symbols are each paired with a single digit. The remainder of the page has a pseudorandomized sequence of these symbols. In the oral version of the SDMT, adapted for the MS population by Rao, the subject responds orally with the digit associated with each of the symbols as quickly as possible, and is scored as the total number of correct responses in 90s.Participants will be evaluated at baseline, week 10 and week 15.

    Time frame: 15 weeks

  2. NLUTD outcome: The Differential Effect, if any, of THC and CBD on Neurogenic lower urinary tract dysfunction (NLUTD) symptoms will be measured by Neurogenic Bladder Symptom Score (NBSS).

    Neurogenic Bladder Symptom Score (NBSS) is a validated measure of bladder symptoms and QoL. It is scored from 0 (no symptoms) to 74 and has 3 domains: incontinence; storage, voiding, and consequences; and a single overall QOL question. Participants will be evaluated at baseline, week 10 and week 15.

    Time frame: 15 weeks

Secondary outcomes

  1. Blinding feasibility: The ability to blind the administration of THC vs CBD in PwMS will be evaluated based on participants and investigators report.

    The investigators will ask subjects at each visit to try and identify which arm they were randomized to. If participants feel they are able to determine which group they were assigned to, they will be asked to identify how/why. This data will help investigators to develop better masking in our subsequent study.

    Time frame: 15 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 21 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Feb 15, 2024
StartActual
Dec 5, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06261489
Collaborators
Multiple Sclerosis Society of Canada
Responsible party
Sponsor
First posted
Feb 15, 2024
Start date
Dec 5, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Sarah A Morrow, MD, MS, FRCPC, FAAN
Contact
sarah.morrow@albertahealthservices.ca
1-403-9444241
Graziela Cerchiaro, PhD, CCRP
Contact
graziela.cerchiaro@albertahealthservices.ca
1-403-9444315

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dronabinol · Cannabidiol

Start the discussion